Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2003 Nov 3;89(9):1697-704.
doi: 10.1038/sj.bjc.6601312.

Serum levels of insulin-like growth factor-I, IGF-binding protein 1 and 3, and insulin and endometrial cancer risk

E Weiderpass  1 , K Brismar, R Bellocco, H Vainio, R Kaaks
Affiliations
Comparative Study

Serum levels of insulin-like growth factor-I, IGF-binding protein 1 and 3, and insulin and endometrial cancer risk

E Weiderpass et al. Br J Cancer. .

Abstract

Insulin-like growth factor-I (IGF-I) and IGF-binding protein-1 and 3 (IGFPB-1, IGFPB-3) are expressed in normal and neoplastic endometrium. Their role and the role of insulin in the aetiology of endometrial cancer, is unclear. We performed a population-based case-control study in Sweden, including 288 endometrial cancer patients and 392 control women and analysed total serum IGF-I, IGFBP-1, IGFBP-3, insulin and BMI levels stratified by disease and hormone replacement therapy status (HRT). Non-parametric statistical tests and logistic regression analyses were performed to assess associations with endometrial cancer. There were no substantial differences between the mean serum levels of IGF-I between cases (115.5, s.d. 61.3) and controls (110.6; s.d. 50.4; Wilcoxon P=0.84), or between subgroups of women classified according to other risk factors for endometrial cancer. There were no trends of increasing risk according to quartiles of IGF-I, IGFBP-1, IGFBP-3 and insulin serum levels. There was an increasing risk of endometrial cancer according to the serum levels of IGFBP-1, which was observed only among women who had ever used HRT. Serum IGF-I, IGFBP-1, IGFBP-3 and insulin levels seem unrelated to endometrial cancer risk. Among users of HRT, increasing IGFBP-1 levels seem to increase endometrial cancer risk.

PubMed Disclaimer

References

    1. Bang P, Eriksson U, Sara V, Wivall I-L, Hall K (1991) Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassay: improvement of determination in acid ethanol extracts by use of truncated IGF-I as radioligand. Acta Endocrinol (Copenh) 124: 620–629 - PubMed
    1. Bergstrom A, Pisani P, Tenet V, Wolk A, Adami HO (2001) Overweight as an avoidable cause of cancer in Europe. Int J Cancer 91: 421–430 - PubMed
    1. Breslow N, Day NE (1980) Statistical Methods in Cancer Research, Vol. 1: The Analysis of Case–Control Studies IARC Scientific Publications No. 32, pp 192–246. Lyon: International Agency for Research on Cancer - PubMed
    1. Brismar K, Fernqvist-Forbes E, Wahren J, Hall K (1994) The effect of insulin on the hepatic secretion of IGFBP-1, IGFBP-3 and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab 79: 872–878 - PubMed
    1. Giudice LC (1994) Growth factors and growth modulators in human uterine endometrium: their potential relevance to reproductive medicine. Fertil Steril 61: 1–17 - PubMed

Publication types

Substances